Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01307631 · ClinicalTrials.gov registry record · Phase 2
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 7
- Study locations
NCT01307631 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT01307631, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Akt Inhibitor MK2206
Study Locations (7)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Charlestown
- Newton-Wellesley Hospital - Newton
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01307631
The ClinicalTrials.gov registry entry for NCT01307631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01307631 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT01307631 about?
NCT01307631 is a clinical study titled "Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer". This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01307631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2011-03. Estimated completion is 2015-09-18.
What conditions does trial NCT01307631 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Endometrial Adenosquamous Carcinoma.
What interventions are being tested in trial NCT01307631?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01307631?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01307631 being conducted?
This trial has 7 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Endometrial Adenocarcinoma
All registered trials for this condition
Endometrial Serous Adenocarcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.